
Figure
2:
A: Axial T1WI after gadolinium injection revealing middle ear enhancing lesion
with anterior extension along the Eustachian tube (arrow). B: Post-contrast
coronal T1WI demonstrating the vascular mass (arrow) and no extension into the
jugular bulb (arrowhead).
During otoscopy, GT appears as a pulsating
reddish-bleu mass behind an intact tympanic membrane also named the ‘‘vascular
tympanic membrane’’ [3,4]. These tumours have a slow growth rate that manifest
through mass effect or by eroding nearby structures. The most frequent sign
includes pulsating tinnitus which affects 82% of patients while 56% experience
hearing loss. Rarely, patients may present vestibular signs, otalgia, or
otorrhagia [1-4]. When the tumour prevents the ossicles from vibrating normally,
conductive hearing loss occurs. In rare cases, sensorineural hearing loss and/
or vertigo might occur if the tumour spreads to the inner ear [1]. Upon
clinical suspicion, imaging is required to confirm the diagnosis. For initial
imaging, a CT scan is typically preferred [4]. GT are recognized by its
distinctive placement in the tympanic cavity, lateral to the cochlear
promontory. They may also indicate the presence of aberrant blood arteries,
particularly an aberrant internal carotid artery [2]. To rule out the
possibility of a glomus jugular tumour, it is crucial to determine whether or
not the jugular bulb is intact [2]. GT are poorly destructive; can grow along
pathways of low resistance [1-3], invade the eustachian tube, and dissect along
fascial planes [2]. On CT scans, they should be divided into those with or
without hypotympanic involvement. This sub-classification would determine the
surgical approach to achieving complete tumour excision [4]. They appear as a
mass of soft tissue adjacent to the middle ear’s promontory. The diagnosis is
almost certain if there is bone or air between the jugular bulb and the tumour
[1]. A further MRI investigation is needed to evaluate hypotympanic extension.
It excludes tumour extension into the jugular bulb wall and outside the middle
ear [4]. Dynamic contrast-enhanced MRI distinguishes the tumour from the
jugular bulb’s blood flow presenting signal-void. On T1, GT typically show
hypointense or intermediate signal (salt and pepper appearance), while on T2
they appear hyperintense. T1-weighted images are helpful in ruling out
intracranial extension, whereas T2-weighted images distinguish GT from
cholesteatoma/middle ear fluid [1-4]. Angiography, if performed will show an
early, strong, and inhomogenous blush of the lesion connected to Jacobson’s
nerve [3]. GT should be distinguished from facial nerve neuroma, middle ear
adenocarcinoma, aberrant internal carotid artery, and high jugular bulb.
Despite the advanced imaging, a correct diagnosis prior to surgery could be challenging
[4]. Nasopharyngeal and middle ear pathologies that spread along the Eustachian
tube should also be considered in the differential diagnosis [2]. Various
classifications exist. Fisch’s classification which was later revised by
Oldring and Fisch is the one frequently used. Type A represents a tympanicum
tumor, one of the four distinct categories defined. Glasscock and Jackson
suggested a second classification separating glomus tympanicum from glomus
jugular tumours [4]. Neither of these systems is optimal in providing the best
surgical indications for tympanicum tumours in this regard [4]. It is prudent
to presume that the jugular bulb is involved if there is any uncertainty and to
treat it like a jugular tumour [4]. It is essential to accurately stage the
tumour before surgery so that appropriate treatment can be planned. The
available treatments could be radiation therapy, surgery, or a combination of
the two. Observation may also be an option [4]. The choice of therapy is
heavily influenced by the stage of the tumour, the patient’s age, and his
general well-being. Follow-up is recommended only for small asymptomatic
lesions [2]. Approximately 40% of irradiated tumours keep growing following
radiation therapy, despite the fact that radiotherapy can momentarily stop
tumour growth. Thus, surgical removal is the best treatment option because of
its minimal risk and favourable outcomes over the long term [4]. Feeding vessel
embolization if done less than 48 hours prior to surgery is beneficial [1].